First Trust Nasdaq Pharmaceuticals ETF Price & Performance (FTXH)

Johnson & Johnson’s robust first-quarter results and dividend increase have boosted sentiment in pharmaceutical ETFs, despite ongoing tariff uncertainty under the Trump administration. The company’s top-selling drugs saw double-digit growth, helping ETFs with significant JNJ exposure outperform broader healthcare benchmarks in a volatile market environment.123

Recent tariff announcements by President Trump triggered sharp swings in biopharma and pharmaceutical ETFs. After a brief rally, funds such as IBB, XBI, and FTXH endured steep declines before recovering some losses. The market’s instability reflects investor anxiety over trade policy and its potential impact on pharmaceutical supply chains.42

LPL Financial raised its holdings in the First Trust Nasdaq Pharmaceuticals ETF by 9.3%, even as the ETF lags with a double-digit decline year-to-date. The move signals selective optimism among institutional investors, despite sector pressures from tariffs and recent dividend cuts affecting pharmaceutical-focused funds.564